MedTrace Logo

Angiogenesis Inhibitors and Hypertension: Clinical Aspects

NCT00511511 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2010-01-05

No results posted yet for this study

Summary

The aim of the study is to find simple clinical and laboratory parameters to predict the development of hypertension and to elucidate the mechanism of hypertension during treatment with the tyrosine kinase inhibitor Sunitinib.

Conditions

Sponsors & Collaborators

Principal Investigators

  • A. H. van den Meiracker, MD, PhD · Erasmus Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Completion
2009-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00511511 on ClinicalTrials.gov